NH Korindo Sekuritas Indonesia
Menu
  • OUR SERVICE
    • News & Research
      • News
      • Equity Report
      • Research Fixed Income
      • Company Report
      • Outlook
      • Special Notation
    • Equity
    • Fixed Income
    • Margin
    • Bonds
    • Investment Banking
      • IPO
      • E-IPO
    • Wealth Management
      • Mutual Funds
    • Download Center
      • Download NAIK
      • Documents
    • Academy
      • Stock Dictionary
      • Stock Education
  • ABOUT US
    • Our Firm
    • Our People
    • Our Branch
    • Corporate Governance
    • Careers
    • FAQ
  • CONTACT
  • Register
  • EN
    • ID
  • ID
  • EN
20 Dec 2021

ICBP – Supported by Topline Growth

ICBP closed 9M21 with an impressive performance. Despite the implementation of stricter public activity restrictions, the company achieved double digit revenue growth in almost all segments. As such, we expect the sales figure continue to remain strong in the upcoming quarter.

07 Dec 2021

ACES – Slowdown in 3Q21 Sales

ACES closed 3Q21 with disappointing result due to a slowdown in SSSG, as the latest sales figure was negatively impacted by unfavourable conditions. However, we are optimistic the company would be back on the recovery track in the upcoming quarter.

01 Dec 2021

ERAA – Continue on Growth Path

ERAA recorded positive performance sales growth during 3Q21, supported by all business segments. We remain optimistic with ERAA due to its strategy to strengthen F&B portfolio and aggressive expansion.

23 Nov 2021

MAPI – Recovery in Sight

MAPI booked underwhelming earnings due to negative SSSG in 3Q21. But, this performance was in line with our expectations considering stricter PPKM implementation. Going forward, company’s turnaround story is still intact with the festive season ahead and gradually lifted restriction.

09 Nov 2021

MIKA – Facing Earnings Normalization

MIKA continues to booked solid performance in 9M21 with strong growth in both inpatient and outpatient segments. For upcoming quarters, we expect there will be normalization of margin and patient traffic volume after Covid-19 peak. Given its strong track record and balance sheet, we believe company’s strategic plan will be achievable.

04 Nov 2021

MYOR – Margins Suppressed by Higher Raw Material Costs

MYOR’s 3Q earnings and margins came out weak due to higher commodity prices and stricter restriction of public activities.

25 Oct 2021

SIDO – New Products Contribute to Sales Growth

SIDO closed 3Q21 with an impressive sales performance, supported by higher demand in herbal segment and supplements. We continue to prefer SIDO as they have strong brand awareness and an extensive portfolio, enabling them to tap into the various market segmentation.

21 Sep 2021

MAPI – Expanding Product Portfolios

MAPI closed 2Q21 with an exciting performance, mainly driven by SSSG improvement and extensive margin expansion. We also believe MAPI’s expansion initiatives may pave the way for a better outlook.

15 Sep 2021

ICBP – Modest Performance amid Declining Margin

ICBP closed 2Q21 with a modest performance, with declining margin across the board due to rising material costs. The company’s performance was slightly below our expectation, which can partly be attributed to slow purchasing power recovery across all consumer sector.

1 2 … 8 Next »

Contact Us

  • Treasury Tower 51th Floor, District 8, SCBD Lot 28, Jl. Jend. Sudirman No.Kav 52-53, RT.5/RW.3, Senayan, Kebayoran Baru, South Jakarta City, Jakarta 12190
  • cso@nhsec.co.id
  • +62 21 5088 9100 (Representative Number)
    +62 21 5088 9102 (CS Number)
  • +628 118 198 111 (Official Whatsapp 1)
    +6281 67 0000 5 (Official Whatsapp 2)

Link

  • Our Firm
  • Research
  • Our People
  • Download
  • Dictionary
  • FAQ

Certified By

Data yang ditampilkan di aplikasi PT NH Korindo Sekuritas Indonesia berasal dari BEI dan telah disetujui untuk ditampilkan.

PT NH Korindo Sekuritas Indonesia berizin dan diawasi oleh Otoritas Jasa Keuangan (OJK).


© Copyright 2026 NH Korindo Sekuritas. All rights reserved.